Table 3.

Symptoms in patients on somatostatin analogue treatment for metastatic disease from small-intestinal neuroendocrine tumour. EORTC GI.NET-21, values expressed as mean (standard deviation) Higher scores (1–100) indicate more severe symptoms

	Baseline	1-year follow-up
Endocrine symptoms	15.6 (17.5)	13.0 (15.7)
Gastrointestinal symptoms	21.2 (15.6)	18.7 (15.5)
Treatment-related symptoms	12.0 (14.1)	10.2 (12.1)
Social functioning	27.8 (19.5)	25.4 (17.7)
Disease-related worries	34.2 (21.5)	30.1 (21.9)
Muscle/bone pain	31.4 (32.9)	25.5 (29.1)
Sexual functioning	29.2 (36.4)	28.6 (37.8)
Information/communication	6.1 (18.6)	5.6 (14.7)
Body image	16.7 (28.6)	13.9 (24.4)